{"id":256880,"date":"2023-09-28T11:15:30","date_gmt":"2023-09-28T10:15:30","guid":{"rendered":"https:\/\/sola-diagnostics.com\/sola-diagnostics\/wideasy-general-wpml\/for-doctors-wpml\/"},"modified":"2026-02-18T19:24:59","modified_gmt":"2026-02-18T18:24:59","slug":"doctors","status":"publish","type":"page","link":"https:\/\/sola-diagnostics.com\/en\/doctors\/","title":{"rendered":"For doctors"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Submen\u00fc&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#7F5E75&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; sticky_position=&#8221;top&#8221; sticky_position_tablet=&#8221;none&#8221; sticky_position_phone=&#8221;none&#8221; sticky_position_last_edited=&#8221;on|phone&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;10px||10px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Georgia||||||||&#8221; text_text_color=&#8221;#FFFCFC&#8221; text_font_size=&#8221;16px&#8221; link_text_color=&#8221;#FFFCFC&#8221; text_orientation=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><a href=\"#sct_1\">Overview<\/a> | <a href=\"#sct_2\">Principle<\/a> | <a href=\"#sct_3\">Indication<\/a> | <a href=\"#sct_4\">Sampling<\/a> | <a href=\"#sct_5\">Performance<\/a> | <a href=\"#sct_6\">Your benefit<\/a> | <a href=\"#sct_7\">Literature<\/a> | <a href=\"#sct_8\">Availability<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Herosection&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; collapsed=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/11\/Canvas-2.png&#8221; title_text=&#8221;Canvas 1&#8243; show_bottom_space=&#8221;off&#8221; align=&#8221;center&#8221; force_fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section &#8211; in aller K\u00fcrze&#8221; module_id=&#8221;sct_1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; collapsed=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;In a nutshell&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<ul>\n<li>Epigenetic DNA methylation test for the detection of all carcinomas originating from the uterus, especially endometrial carcinoma, but also endocervical carcinoma.<\/li>\n<li>The test is indicated in peri- and postmenopausal women with abnormal uterine bleeding.<\/li>\n<li>Sample collection by cervicovaginal swab.<\/li>\n<li>95% less false positives compared to transvaginal sonography.<\/li>\n<li>The test reduces the number of women who have to undergo hysteroscopy with curettage by 90%.<\/li>\n<li>A negative WID\u00ae-easy test result indicates a high probability that there is no malignancy, so that conservative treatment and active monitoring are an alternative to hospital referral for many patients.<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Divider&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; saved_tabs=&#8221;all&#8221; collapsed=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider color=&#8221;#7F5E75&#8243; divider_position=&#8221;center&#8221; divider_weight=&#8221;2px&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section &#8211; das Prinzip des WID-easy Tests&#8221; module_id=&#8221;sct_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; collapsed=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row module_id=&#8221;Prinzip&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;The principle of the WID\u00ae-easy test &#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_heading title=&#8221;Indication&#8221; module_id=&#8221;sct_3&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span>Test for simple and rapid screening of women presenting with symptoms suggestive of endometrial cancer. These are particularly peri- and postmenopausal women with abnormal uterine bleeding. <\/span><\/p>\n<p>[\/et_pb_text][et_pb_heading title=&#8221;The procedure &#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_video src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/01\/Sola_Diagnostics_WID_HighRes_Final_EasyTest.mp4&#8243; module_id=&#8221;autoplay-video&#8221; module_class=&#8221;autoplay-video&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; max_width=&#8221;60%&#8221; max_width_tablet=&#8221;100%&#8221; max_width_phone=&#8221;100%&#8221; max_width_last_edited=&#8221;on|phone&#8221; module_alignment=&#8221;center&#8221; box_shadow_style=&#8221;preset1&#8243; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_video][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span>A cervicovaginal swab is sent to the diagnostic laboratory.<\/span><\/p>\n<p><span>After DNA extraction and bisulfite conversion, a quantitative PCR reaction is performed.<\/span><\/p>\n<p><span>The WID\u00ae-easy test, which is referred to in the scientific literature as &#8220;WID-qEC test&#8221;, measures the methylation status of DNA regions of the <em>GYPC<\/em> and <em>ZSCAN12<\/em> genes, which are known to be highly methylated in endometrial cancer and cervical cancer.<\/span><\/p>\n<p>These measured values (indicated in &#8220;PMR&#8221; = &#8220;Percentage of fully Methylated Reference&#8221;) are summed to give &#8220;\u2211 PMR&#8221;. The result of the test depends on the determined value \u2211 PMR and is provided to the physician in the test report.<\/p>\n<p>Sources: <a href=\"http:\/\/www.eutops.institute\" target=\"_blank\" rel=\"noopener\">www.eutops.institute<\/a> and <a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(23)00466-7\/fulltext\" target=\"_blank\" rel=\"noopener\">Evans et al, The Lancet Oncology, 2023<\/a><\/p>\n<p>[\/et_pb_text][et_pb_code _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<script><!-- [et_pb_line_break_holder] -->jQuery(document).ready(function() {<!-- [et_pb_line_break_holder] -->    if (jQuery('.autoplay-video .et_pb_video_box').length !== 0) {<!-- [et_pb_line_break_holder] -->        jQuery('.autoplay-video .et_pb_video_box').find('video').prop('muted', true);<!-- [et_pb_line_break_holder] -->        jQuery(\".autoplay-video .et_pb_video_box\").find('video').attr('loop', 'loop');<!-- [et_pb_line_break_holder] -->        jQuery(\".autoplay-video .et_pb_video_box\").find('video').attr('playsInline', '');<!-- [et_pb_line_break_holder] -->        jQuery(\".autoplay-video .et_pb_video_box\").each(function() {<!-- [et_pb_line_break_holder] -->            jQuery(this).find('video').get(0).play();<!-- [et_pb_line_break_holder] -->        })<!-- [et_pb_line_break_holder] -->    }<!-- [et_pb_line_break_holder] -->});<!-- [et_pb_line_break_holder] --><\/script>[\/et_pb_code][et_pb_heading title=&#8221;The test result&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>The test result will be available to you in a few days. Please ask your laboratory for the current processing times (sample receipt in the laboratory until the report is issued) for the WID\u00ae-easy test.<\/p>\n<p>The report states the \u2211PMR value determined and an interpretation of the result based on <a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(23)00466-7\/fulltext\" target=\"_blank\" rel=\"noopener\">Evans et al., 2023<\/a>. The <span>formulation of the test result is the responsibility of the healthcare facility that produces and uses the test<\/span>.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Divider&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; saved_tabs=&#8221;all&#8221; collapsed=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider color=&#8221;#7F5E75&#8243; divider_position=&#8221;center&#8221; divider_weight=&#8221;2px&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section &#8211; Probennahme&#8221; module_id=&#8221;sct_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; collapsed=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row admin_label=&#8221;Row&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;The sampling*&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||16px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Sampling is carried out using a Copan swab and medium.<\/p>\n<p>[\/et_pb_text][et_pb_blurb title=&#8221;Copan Swab and Medium&#8221; image=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/09\/eNat-6C057N.RUO-SampleCollectionAndTransport-0619-01a-500&#215;462-1.png&#8221; image_icon_width=&#8221;80%&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; header_text_align=&#8221;center&#8221; body_font_size=&#8221;15px&#8221; max_width=&#8221;60%&#8221; max_width_tablet=&#8221;100%&#8221; max_width_phone=&#8221;100%&#8221; max_width_last_edited=&#8221;on|phone&#8221; module_alignment=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: center;\">Sampling is carried out using the Copan FLOQswab\u2122 (552C.80PB) and the eNAT medium (608C) from Copan, which also offers a corresponding kit (608CS01R). Both will be provided to you by your laboratory.<\/p>\n<p>[\/et_pb_blurb][et_pb_heading title=&#8221;The procedure&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#504756&#8243; custom_margin=&#8221;-30px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span style=\"text-decoration: underline;\"><strong>Do not use any lubricant<\/strong><\/span> before taking the sample for the WID\u00ae-easy test.<\/p>\n<p>The sample collection for the WID\u00ae-easy test takes place<\/p>\n<ul>\n<li><span style=\"text-decoration: underline;\"><strong>before<\/strong><\/span> taking a sample for another test, e.g., for a PAP smear.<\/li>\n<li><span style=\"text-decoration: underline;\"><strong>before<\/strong><\/span> inserting another substance into the vagina or near the cervix, such as acetic acid, for visual inspection (VIA).<\/li>\n<li><span style=\"text-decoration: underline;\"><strong>before<\/strong><\/span> transvaginal sonography<\/li>\n<li>or at the earliest three days after these measures.<\/li>\n<\/ul>\n<p>Detailed instructions on sampling can be found at the following link*.<\/p>\n<p><a href=\"https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2024\/02\/Sampling-Instruction-vers3.pdf\" target=\"_blank\" rel=\"noopener\">Download &#8220;Sampling instructions&#8221;<\/a><\/p>\n<p>[\/et_pb_text][et_pb_heading title=&#8221;Limitations&#8221; admin_label=&#8221;Heading&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>The WID\u00ae-easy test detects the methylation patterns of tumor DNA indicative of endometrial cancer.<\/p>\n<p>Conditions that restrict the drainage of tumor DNA from the uterine cavity into the vagina, such as large endocervical polyps or fibroids, may affect the sensitivity of the test.<\/p>\n<p>The patient should not have vaginal intercourse without using a condom for at least 24 hours before taking the WID\u00ae-easy test.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;14px&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>* The specific instructions for sampling are the responsibility of the healthcare facility that produces and uses the test. These instructions will be provided by the health institution. The example presented here is a current working hypothesis.<\/p>\n<p>[\/et_pb_text][et_pb_heading title=&#8221;S3 guideline endometrial cancer&#8221; admin_label=&#8221;Heading&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_blurb title=&#8221;Diagnostic pathway for patients with postmenopausal bleeding&#8221; image=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/09\/Postmenopausal-Englisch-1.png&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; header_text_align=&#8221;center&#8221; body_font_size=&#8221;15px&#8221; text_orientation=&#8221;center&#8221; max_width=&#8221;60%&#8221; max_width_tablet=&#8221;100%&#8221; max_width_phone=&#8221;100%&#8221; max_width_last_edited=&#8221;on|phone&#8221; module_alignment=&#8221;center&#8221; header_text_align_tablet=&#8221;center&#8221; header_text_align_last_edited=&#8221;off|desktop&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10427205\/\" target=\"_blank\" rel=\"noopener\">S3 guideline endometrial carcinoma AWMF register number: 032\/034-OL from September 2022<\/a><\/p>\n<p>[\/et_pb_blurb][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>According to the current S3 guideline on endometrial carcinoma (AWMF register number: 032\/034-OL, September 2022), transvaginal sonography as well as a cytological examination, are recommended after clinical examination.<\/p>\n<p>Transvaginal sonography determines the endometrial thickness and, if the thickness is \u2265 3 mm, surgical, diagnostic procedures such as Tao Brush\u2122, Pipelle\u2122, hysteroscopy and curettage are recommended.<\/p>\n<p>In women with peri- and postmenopausal abnormal bleeding, this threshold is reached or exceeded in over 50% of cases.<br \/><a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(23)00466-7\/fulltext\" target=\"_blank\" rel=\"noopener\">(Evans et al., The Lancet Oncology, 2023<\/a>).<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Divider&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; saved_tabs=&#8221;all&#8221; collapsed=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider color=&#8221;#7F5E75&#8243; divider_position=&#8221;center&#8221; divider_weight=&#8221;2px&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section &#8211; Leistung&#8221; module_id=&#8221;sct_5&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; collapsed=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;The performance of the WID\u00ae-easy test compared to the transvaginal sonographic examination&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; custom_css_free_form=&#8221;@media (max-width: 399px) { \/* Beispiel: Bis 768px Breite *\/||    selector {||        display: none; \/* Element ausblenden *\/||    }||}||@media (min-width: 400px) { \/* Beispiel: Ab 768px Breite *\/||    selector {||        display: block; \/* Element anzeigen *\/||    }||}&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_heading title=&#8221;The performance of the WID\u00ae-easy test compared to the transvaginal ultrasound examination&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; custom_css_free_form=&#8221;@media (max-width: 399px) { \/* Beispiel: Bis 768px Breite *\/||    selector {||        display: block; \/* Element ausblenden *\/||    }||}||@media (min-width: 400px) { \/* Beispiel: Ab 768px Breite *\/||    selector {||        display: none; \/* Element anzeigen *\/||    }||}&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_image src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/11\/Performance-Englisch.png&#8221; title_text=&#8221;Performance vs TVS Englisch&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; max_width=&#8221;60%&#8221; max_width_tablet=&#8221;100%&#8221; max_width_phone=&#8221;100%&#8221; max_width_last_edited=&#8221;on|desktop&#8221; module_alignment=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-3px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>The WID\u00ae-easy test is characterized by extremely high values for sensitivity (90.9%), specificity (97.3%) and NPV (99.7%).<\/p>\n<p>Using the \u2211PMR cut-off value of 0.3, the PPV of the WID\u00ae-easy test is 50 %, ten times higher than that of sonography, whose PPV is only 5 %.<br \/><a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(23)00466-7\/fulltext\" target=\"_blank\" rel=\"noopener\">(Evans et al., The Lancet Oncology, 2023<\/a>)<\/p>\n<p>[\/et_pb_text][et_pb_heading title=&#8221;90 % less surgical diagnostic procedures&#8221; admin_label=&#8221;90 % weniger operative diagnostische Eingriffe&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_2,1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Georgia|700|on||||||&#8221; text_text_color=&#8221;#7F5E75&#8243; text_font_size=&#8221;19px&#8221; text_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;center&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Over 50% false positive<br \/>on ultrasound<\/p>\n<p>[\/et_pb_text][et_pb_image src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2024\/02\/Manderl-TVU-EN.001.png&#8221; title_text=&#8221;_Graphik M\u00e4nchen mit Gelb english.001&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;15px&#8221; text_orientation=&#8221;center&#8221; max_width=&#8221;80%&#8221; max_width_tablet=&#8221;80%&#8221; max_width_phone=&#8221;80%&#8221; max_width_last_edited=&#8221;on|desktop&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||30px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: center;\">The gray area indicates the proportion (&gt; 55%) of women with peri- or postmenopausal bleeding who need to undergo a surgical diagnostic procedure based on the determination of endometrial thickness by transvaginal sonography, although cancer is present in less than 3% of these women. This is a false positive rate of over 50%.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Georgia|700|on||||||&#8221; text_text_color=&#8221;#7F5E75&#8243; text_font_size=&#8221;19px&#8221; text_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;center&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Less than 3 % false positives<br \/>with WID\u00ae-easy test<\/p>\n<p>[\/et_pb_text][et_pb_image src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2024\/02\/Manderl-WID-EN.002.png&#8221; title_text=&#8221;_Graphik M\u00e4nchen mit Gelb english.002&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;15px&#8221; text_orientation=&#8221;center&#8221; max_width=&#8221;80%&#8221; max_width_tablet=&#8221;80%&#8221; max_width_phone=&#8221;80%&#8221; max_width_last_edited=&#8221;on|desktop&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||30px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>The proportion (5.2%) of women with peri- or postmenopausal bleeding who need to undergo a surgical diagnostic procedure due to a positive WID\u00ae-easy test result is shown here in gray. The proportion of false positive results is less than 3%. That&#8217;s a 95% reduction in false positives.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Extrapolated to 100 peri- and postmenopausal women presenting with abnormal bleeding, transvaginal sonography (&#8220;TVS&#8221;) will exceed the 3-mm threshold for endometrial thickness in 55 women. According to the S3 guidelines, all these women must undergo a surgical diagnostic workup (Tao Brush\u2122, Pipelle\u2122, hysteroscopy or curettage). More than 50 of these women will be found not to have endometrial or cervical cancer. Thus, a false positive result was present. <\/p>\n<p>Because of the higher specificity of the WID\u00ae-easy test (97.3% WID\u00ae-easy \/ 45.8% TVU), which results in a significantly higher positive predictive value compared with transvaginal ultrasound (PPV 50.0% WID\u00ae-easy \/ 4.9% TVU), the WID\u00ae-easy test suggests invasive workup in only five women. That&#8217;s a 90% reduction in invasive procedures. Half of these women will be diagnosed with cancer in the histological examination.<\/p>\n<p><span>The false positive rate is twenty times higher with ultrasound than with the WID\u00ae-easy test (52.6% vs. 2.6%). Using the WID\u00ae-easy test can therefore avoid 95% of invasive diagnostic procedures in women who are ultimately found not to have endometrial cancer.<\/span><\/p>\n<p>Sensitivity, the negative predictive value (NPV) and the rate of false negative results are comparable for both methods.<br \/><a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(23)00466-7\/fulltext\" target=\"_blank\" rel=\"noopener\">(Evans et al., The Lancet Oncology, 2023<\/a>)<\/p>\n<p>[\/et_pb_text][et_pb_heading title=&#8221;Robustness and complications&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_blurb title=&#8221;WID\u00ae-easy test compared to TVS, Pipelle\u2122 and Tao Brush\u2122&#8221; image=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/09\/Methodenvergleich-EN-1.png&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; body_font_size=&#8221;15px&#8221; text_orientation=&#8221;center&#8221; max_width=&#8221;60%&#8221; max_width_tablet=&#8221;100%&#8221; max_width_phone=&#8221;100%&#8221; max_width_last_edited=&#8221;on|desktop&#8221; module_alignment=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>In contrast to examinations using transvaginal sonography, Pipelle\u2122 or Tao Brush\u2122, performing the WID\u00ae-easy test almost always (98%) leads to a clear result and no complications are to be expected.<\/p>\n<p>[\/et_pb_blurb][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;11px&#8221; text_line_height=&#8221;1.4em&#8221; max_width=&#8221;60%&#8221; max_width_tablet=&#8221;100%&#8221; max_width_phone=&#8221;100%&#8221; max_width_last_edited=&#8221;on|phone&#8221; custom_margin=&#8221;0px||||false|false&#8221; module_alignment_tablet=&#8221;&#8221; module_alignment_phone=&#8221;left&#8221; module_alignment_last_edited=&#8221;on|desktop&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"padding-left: 40px;\">Sources:<br \/>(1) <a href=\"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1002\/uog.23667\" target=\"_blank\" rel=\"noopener\">Goldstein et al., Ultrasound in Obstetrics Gynecology, 2021<\/a><br \/>(2) <a href=\"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-0528.2008.01773.x\" target=\"_blank\" rel=\"noopener\">Williams et al., BJOG: An International Journal of Obstetrics Gynecology, 2008<\/a><br \/>(3) <a href=\"https:\/\/www.gynecologiconcology-online.net\/article\/S0090-8258(16)31610-9\/fulltext\" target=\"_blank\" rel=\"noopener\">Adambekov et al., Gynecologic Oncology, 2017<\/a><br \/>(4) <a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(23)00466-7\/fulltext\" target=\"_blank\" rel=\"noopener\">Evans et al., The Lancet Oncology, 2023<\/a><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>In addition to the convincing performance of the WID\u00ae-easy test (sensitivity, specificity, NPV, PPV), the test is also characterized by superior robustness. Furthermore, it can be assumed that the test will not lead to any complications.<\/p>\n<p>In almost 40% of cases, transvaginal sonography and the Tao Brush\u2122 must be expected not to yield a conclusive result. In the Pipelle\u2122 test, the expected value for the proportion of unambiguous results tends to be below 50%.<\/p>\n<p>Performing the WID\u00ae-easy test, on the other hand, almost always leads to an unambiguous result (98 %).<\/p>\n<p>Pipelle\u2122 and Tao Brush\u2122 examinations require insertion of the instruments through the cervical canal into the uterus. This can result in pain or infection, and in some cases even perforation of the uterus.<\/p>\n<p>[\/et_pb_text][et_pb_heading title=&#8221;Endocervical carcinoma&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_blurb title=&#8221;Endocervical carcinoma&#8221; image=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/09\/Bildschirmfoto-2023-09-30-um-18.16.02-e1696174452895.png&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; header_text_align=&#8221;center&#8221; body_text_align=&#8221;center&#8221; body_font_size=&#8221;15px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Endocervical carcinomas cannot be detected during visual inspection using a speculum. Furthermore, these do not lead to an increased endometrial thickness and also remain inconspicuous in cytology.<\/p>\n<p>In a case-control study, the WID\u00ae-easy test detected 21 of 22 cervical carcinomas, giving it a sensitivity of 95 %<br \/><a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.34275\" target=\"_blank\" rel=\"noopener\">(Schreiberhuber et al., International Journal of Cancer, 2022<\/a>).<\/p>\n<p>[\/et_pb_blurb][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Divider&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; saved_tabs=&#8221;all&#8221; collapsed=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider color=&#8221;#7F5E75&#8243; divider_position=&#8221;center&#8221; divider_weight=&#8221;2px&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section &#8211; ihr Vorteil&#8221; module_id=&#8221;sct_6&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; collapsed=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;More conservative treatments&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>When endometrial cancer is suspected, rapid workup is critical to maximize survival if endometrial cancer is indeed present <a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(20)30392-2\/fulltext\" target=\"_blank\" rel=\"noopener\">(Sud et al., The Lancet Oncology, 2020<\/a>).<\/p>\n<p>In case of a negative WID\u00ae-easy test, conservative treatment of women with abnormal bleeding and active monitoring with transvaginal ultrasound and the WID\u00ae-easy test is a real option.<\/p>\n<p>You spare your patient a surgical intervention in the hospital and remain in close contact with your patient as her primary contact person during the conservative treatment.<\/p>\n<p>[\/et_pb_text][et_pb_image src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/10\/iStock-1333488058.jpg&#8221; title_text=&#8221;Shot of a doctor using a digital tablet during a consultation with a woman&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; max_width=&#8221;60%&#8221; max_width_tablet=&#8221;100%&#8221; max_width_phone=&#8221;100%&#8221; max_width_last_edited=&#8221;on|desktop&#8221; module_alignment=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Divider&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; saved_tabs=&#8221;all&#8221; collapsed=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider color=&#8221;#7F5E75&#8243; divider_position=&#8221;center&#8221; divider_weight=&#8221;2px&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section &#8211; Literatur&#8221; module_id=&#8221;sct_7&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; custom_margin=&#8221;||||false|false&#8221; animation_direction=&#8221;top&#8221; locked=&#8221;off&#8221; collapsed=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Scientific publications on the WID\u00ae-easy test&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,2_3&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;&#038;nbsp&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_image src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/09\/Lancet.png&#8221; title_text=&#8221;Lancet&#8221; url=&#8221;https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(23)00466-7\/fulltext&#8221; url_new_window=&#8221;on&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Evans et al. (2023)&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h4&#8243; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;10px&#8221; text_line_height=&#8221;1.2em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><span>Evans, I., Reisel, D., Jones, A., Bajrami, A., Nijjar, S., Solangon, S. A., Arora, R., Redl, E., Schreiberhuber, L., Ishaq-Parveen, I., Roth\u00e4rmel, J., Herzog, C., Jurkovic, D. &amp; Widschwendter, M. (2023). Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK.   <\/span><i>The Lancet Oncology<\/i><span>, <\/span><i>24<\/i><span>(12), 1375-1386. <\/span><span class=\"url\">https:\/\/doi.org\/10.1016\/s1470-2045(23)00466-7<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Real-life comparison to the state of the art&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>A prospective study was conducted to compare the performance of the current improved version of the WID-qEC test with the standard procedure in the United Kingdom. The study took place at UCL-Hospital in London.<\/p>\n<p>400 women aged 45 years and older with peri- or postmenopausal abnormal bleeding participated in the study.<\/p>\n<p>The WID-qEC test reduces the number of women who need surgical diagnostic procedures such as hysteroscopy and curettage, even though they do not have cancer, by 87% compared to the standard procedure in the UK and by 95% compared to the standard procedure in Germany, Switzerland and Austria.<\/p>\n<p>The WID-qEC test speeds up diagnosis in women with symptoms of endometrial cancer, leading to better outcomes and healthcare cost savings.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(23)00466-7\/fulltext&#8221; url_new_window=&#8221;on&#8221; button_text=&#8221;Link to the Lancet paper&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; transform_scale=&#8221;80%|80%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,2_3&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;&#038;nbsp&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_image src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/09\/JCO.png&#8221; title_text=&#8221;JCO&#8221; url=&#8221;https:\/\/ascopubs.org\/doi\/10.1200\/JCO.22.00266&#8243; url_new_window=&#8221;on&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Herzog et al. (2022)&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h4&#8243; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;10px&#8221; text_line_height=&#8221;1.2em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div>\n<p>Herzog, C., Mar\u00edn, F., Jones, A., Evans, I., Reisel, D., Redl, E., Schreiberhuber, L., Paytubi, S., Pelegrina, B., Carmona, \u00c1., Peremiquel-Trillas, P., Frias-Gomez, J., Pineda, M., Brunet, J., Ponce, J., Matias-Guiu, X., De Sanjos\u00e9, S., Alemany, L., Olaitan, A., . . Widschwendter, M. (2022). A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case\/Control Sets. <i>Journal Of Clinical Oncology<\/i>, <i>40<\/i>(33), 3828-3838. <span class=\"url\">https:\/\/doi.org\/10.1200\/jco.22.00266<\/span><\/p>\n<\/div>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Development and validation in five different settings&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>This publication describes the development and validation of the WID-qEC test.<\/p>\n<p>The test was developed using 726 cervicovaginal smears from women with and without endometrial cancer and validated in 562 unrelated cervicovaginal specimens using three different collection methods and two diagnostic and two predictive settings.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;https:\/\/ascopubs.org\/doi\/10.1200\/JCO.22.00266&#8243; url_new_window=&#8221;on&#8221; button_text=&#8221;Link to the JCO paper&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; transform_scale=&#8221;80%|80%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,2_3&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;&#038;nbsp&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_image src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/09\/IJC.png&#8221; title_text=&#8221;IJC&#8221; url=&#8221;https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.34275&#8243; url_new_window=&#8221;on&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Schreiberhuber et al. (2022)&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h4&#8243; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;10px&#8221; text_line_height=&#8221;1.2em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div>\n<p>Schreiberhuber, L., Herzog, C., Vavourakis, C. D., Redl, E., Kastner, C., Jones, A., Evans, I., Zikan, M., Cibula, D., Widschwendter, P., Pfau, K., Math, B., Seewald, M., Amory, S., Obrist, P. &amp; Widschwendter, M. (2022). The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers. <i>International Journal Of Cancer<\/i>, <i>152<\/i>(6), 1269-1274. <span class=\"url\">https:\/\/doi.org\/10.1002\/ijc.34275<\/span> <\/p>\n<\/div>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Real-life cohort and validation for cervical cancer.&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>WID-qEC test was validated in a real-life hospital cohort of 304 women.<\/p>\n<p>In addition, a case-control study showed the superiority of the WID-qEC test in the detection of cervical carcinoma, especially endocervical carcinoma, compared to cytological examination.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.34275&#8243; url_new_window=&#8221;on&#8221; button_text=&#8221;Link to the IJC paper&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; transform_scale=&#8221;80%|80%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,2_3&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;&#038;nbsp&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_image src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/12\/Bildschirmfoto_2023-12-22_um_18.02.04-removebg-preview.png&#8221; title_text=&#8221;Bildschirmfoto_2023-12-22_um_18.02.04-removebg-preview&#8221; url=&#8221;https:\/\/analyticalscience.wiley.com\/content\/article-do\/high-throughput-implementation-wid-qec-test&#8221; url_new_window=&#8221;on&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Redl et al. (2024)&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h4&#8243; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;10px&#8221; text_line_height=&#8221;1.2em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Redl, E., Schreiberhuber, L., Ishaq, I., &amp; Widschwendter, M. (2024). High-throughput implementation of the WID-qEC Test: DNA methylation-based test for the detection of uterine cancers.   <i>Wiley Analytical Science.<\/i><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Development of the high-throughput analytics&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>The article describes the technical implementation and the analytical verification of the WID-qEC test.<\/p>\n<p>The described workflow includes not only the qPCR analysis itself but also the entire test process, including sample collection, automated DNA isolation, quantification and normalization and automated bisulfite conversion as well as downstream analysis and data interpretation.<\/p>\n<p>This process allows laboratories to process a large number of samples exceptionally efficiently.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;https:\/\/analyticalscience.wiley.com\/content\/article-do\/high-throughput-implementation-wid-qec-test&#8221; url_new_window=&#8221;on&#8221; button_text=&#8221;Link to the WAS paper&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; transform_scale=&#8221;80%|80%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,2_3&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;&#038;nbsp&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_image src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/09\/IJC.png&#8221; title_text=&#8221;IJC&#8221; url=&#8221;https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.35000&#8243; url_new_window=&#8221;on&#8221; admin_label=&#8221;Image&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Illah et al. (2024)&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h4&#8243; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;10px&#8221; text_line_height=&#8221;1.2em&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p>Illah, O., Scott, M., Redl, E., Barrett, J. E., Schreiberhuber, L., Herzog, C., Vavourakis, C. D., Jones, A., Evans, I., Reisel, D., Chandrasekaran, D., Doufekas, K., Graham, R., Kotsopoulos, I. C., MacDonald, N., Arora, R., Olaitan, A., Rosenthal, A. &amp; Widschwendter, M. (2024). High performance of the DNA methylation\u2010based WID\u2010qEC test for detecting uterine cancers independent of sampling modalities. <em>International Journal Of Cancer<\/em>, 155(5), 800\u2013806. https:\/\/doi.org\/10.1002\/ijc.35000<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Comparison of different sampling methods&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>The study investigated whether different sampling methods influence the validity of the test. Specifically, it compared Cervex brush with PreservCyt against FLOQSwab with eNAT, physician-performed sampling with patient self-sampling, and the exact sampling site (vaginal, cervico-vaginal, or cervical) to assess their influence on the test\u2019s performance.<\/p>\n<p>The results demonstrated that the test results remained consistent irrespective of the sampling method, even for samples stored at room temperature for seven days. While self-sampling led to high specificity, the sensitivity was somewhat lower.<\/p>\n<p>Overall, the WID-qEC test offers a simple, objective and non-invasive method for assessing the risk of malignancy in women with abnormal bleeding.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.35000&#8243; url_new_window=&#8221;on&#8221; button_text=&#8221;Link to the IJC paper&#8221; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; transform_scale=&#8221;80%|80%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,2_3&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;&#038;nbsp&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_image src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/09\/IJC.png&#8221; title_text=&#8221;IJC&#8221; url=&#8221;https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.35260&#8243; url_new_window=&#8221;on&#8221; admin_label=&#8221;Image&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Ken-Amoah et al. (2024)&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h4&#8243; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;10px&#8221; text_line_height=&#8221;1.2em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div>\n<p>Ken-Amoah, S., Redl, E., Domson, B. K. S., Barrett, J. E., Schreiberhuber, L., Herzog, C., Arora, R., Jones, A., Evans, I., Reisel, D., Lamptey-Mills, E., Nachinab, V. B., Pepera, T., Olaitan, A., Obiri-Yeboah, D., Akakpo, P. K. &amp; Widschwendter, M. (2024). Performance of the WID-qEC test to detect uterine cancers in black women with abnormal uterine bleeding: A prospective observational cohort study in Ghana. <i>International Journal Of Cancer<\/i>, <i>156<\/i>(5), 1055-1064. <span class=\"url\">https:\/\/doi.org\/10.1002\/ijc.35260<\/span> <\/p>\n<\/div>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Performance of the WID-qEC test to detect uterine cancers in black women with abnormal uterine bleeding&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>The authors investigated the ability of WID-qEC testing to detect endometrial and cervical cancer in black women in Ghana who presented with abnormal uterine bleeding.<\/p>\n<p>The WID-qEC test successfully identified 100% of endometrial and cervical cancers in the study population. The ease of sample collection and low-cost, high-throughput PCR-based analysis makes the WID-qEC test a promising tool for detecting endometrial cancer in all women in low- and middle-income countries and in ethnic groups where sonography performance is known to be particularly poor. <\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.35260&#8243; url_new_window=&#8221;on&#8221; button_text=&#8221;Link to the IJC paper&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; transform_scale=&#8221;80%|80%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,2_3&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;&#038;nbsp&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_image src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/09\/IJC.png&#8221; title_text=&#8221;IJC&#8221; url=&#8221;https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70354&#8243; url_new_window=&#8221;on&#8221; admin_label=&#8221;Image&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_heading title=&#8221;Redl et al. (2026)&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h4&#8243; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; text_font_size=&#8221;10px&#8221; text_line_height=&#8221;1.2em&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p>Redl, E., Herzog, C., Vavourakis, C., Barrett, J., Jones, A., Evans, I., Reisel, D., Manchanda, R., Bj\u00f8rge, L., Zikan, M., Cibula, D., Alkasalias, T., R\u00e5destad, A. F., Gemzell-Danielsson, K., Dubeau, L., MacDonald, N., Jurkovic, D., Pashayan, N. &amp; Widschwendter, M. (2026). The cervico-vaginal DNA methylation WID-qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer. <em>International Journal Of Cancer<\/em>, 1-7. doi:10.1002\/ijc.70354<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;WID\u00ae-easy Positivity and Ovarian Cancer Association&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>The study assessed WID\u00ae-easy (WID-qEC) positivity in women without cervical or endometrial cancer. Among 1,269 samples, 6.3% were positive. Ovarian cancer was the strongest independent predictor of positivity (adjusted OR 2.93), and higher lifetime ovulatory cycles were also independently associated with positivity.<\/p>\n<p>In a modelled symptomatic population with a baseline ovarian cancer prevalence of 0.38%, WID-qEC positivity corresponds to an estimated probability of approximately 1.3%\u2014a clear increase over baseline, although the absolute risk remains low.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70354&#8243; url_new_window=&#8221;on&#8221; button_text=&#8221;Link to the IJC paper&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; transform_scale=&#8221;80%|80%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Divider&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; saved_tabs=&#8221;all&#8221; collapsed=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider color=&#8221;#7F5E75&#8243; divider_position=&#8221;center&#8221; divider_weight=&#8221;2px&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Section &#8211; Verf\u00fcgbarkeit&#8221; module_id=&#8221;sct_8&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFCFC&#8221; collapsed=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_heading title=&#8221;Are you interested in the WID\u00ae-easy test?&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_level=&#8221;h2&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;||||false|false&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>In the European Union and Switzerland, the WID\u00ae-easy test is manufactured and used by healthcare facilities, such as diagnostic laboratories, in accordance with the European In Vitro Diagnostics Regulation (IVDR) Article 5, paragraph 5, or corresponding national regulations.<\/p>\n<p>In the UK, the WID\u00ae-easy test is labelled in accordance with the UK Medical Devices Regulations 2002 (SI 2002 No. 618, as amended) (UK MDR 2002)<\/p>\n<p>Partners who currently offer the WID\u00ae-easy test can be found on the map below. Please contact one of these providers directly to obtain the necessary documents and materials for commissioning, sampling and logistics. <\/p>\n<p>[\/et_pb_text][et_pb_map address=&#8221;Salzburg, \u00d6sterreich&#8221; zoom_level=&#8221;7&#8243; address_lat=&#8221;47.011239883094&#8243; address_lng=&#8221;13.0448441&#8243; disabled_on=&#8221;on|on|on&#8221; admin_label=&#8221;Karte&#8221; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; disabled=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_map_pin title=&#8221;Tyrolpath Obrist Brunhuber GmbH&#8221; pin_address=&#8221;Hauptpl. 4, 6511 Zams, \u00d6sterreich&#8221; pin_address_lat=&#8221;47.1584101&#8243; pin_address_lng=&#8221;10.5898104&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div data-colibri-id=\"1053-f10\" class=\"h-text h-text-component style-365 style-local-1053-f10 position-relative h-element\">\n<div class=\"\">\n<p>Hauptplatz 4<br \/>6511 Zams, Austria<\/p>\n<p>Tel: +43 5442 666 11<br \/>Mail: <a href=\"mailto:office@tyrolpath.at\" target=\"_blank\" rel=\"noopener\">office@tyrolpath.at<\/a><br \/>Web: <a href=\"https:\/\/tyrolpath.at\" target=\"_blank\" rel=\"noopener\">https:\/\/tyrolpath.at<\/a><\/p>\n<\/div>\n<\/div>\n<p>[\/et_pb_map_pin][et_pb_map_pin title=&#8221;labor team w ag&#8221; pin_address=&#8221;Blumeneggstrasse 55, 9403 Goldach, Schweiz&#8221; pin_address_lat=&#8221;47.4684725&#8243; pin_address_lng=&#8221;9.4514751&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Blumeneggstrasse 55<br \/>9403 Goldach, Switzerland<\/p>\n<p>Tel: +41 71 844 45 45<br \/>Mail: <a href=\"mailto:info@team-w.ch\" target=\"_blank\" rel=\"noopener\">info@team-w.ch<\/a><br \/>Web: <a href=\"https:\/\/www.laborteam.ch\" target=\"_blank\" rel=\"noopener\">https:\/\/www.laborteam.ch<\/a><\/p>\n<p>[\/et_pb_map_pin][et_pb_map_pin title=&#8221;Laboratory &#8211; Doz. DDr. Stefan Mustafa  &#8221; pin_address=&#8221;Ziehrerpl. 9, 1030 Wien, \u00d6sterreich&#8221; pin_address_lat=&#8221;48.2000033&#8243; pin_address_lng=&#8221;16.3912123&#8243; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Ziehrerplatz 9<br \/>1030 Vienna, Austria<\/p>\n<p>Tel: +43 1 713 91 88<br \/>Mail: <a href=\"mailto:office@labor-mustafa.at\" target=\"_blank\" rel=\"noopener\">office@labor-mustafa.at<\/a><br \/>Web: <a href=\"https:\/\/www.labor-mustafa.at\" target=\"_blank\" rel=\"noopener\">https:\/\/www.labor-mustafa.at<\/a><\/p>\n<p>[\/et_pb_map_pin][\/et_pb_map][et_pb_image src=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/10\/Karte_v9.png&#8221; title_text=&#8221;Map_v9&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider color=&#8221;#7F5E75&#8243; divider_position=&#8221;center&#8221; divider_weight=&#8221;2px&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,1_4,1_4,1_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_team_member name=&#8221;Advanced Global Health Ltd&#8221; position=&#8221;30 Great Guildford Street, London, Great Britain  &#8221; image_url=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2024\/12\/AGHealth.png&#8221; admin_label=&#8221;AGHealth&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; link_option_url=&#8221;https:\/\/www.aghealth.co.uk\/wid-easy&#8221; link_option_url_new_window=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Tel: +44 207 078 8867<br \/>Mail: <a href=\"mailto:info@aghealth.co.uk\" target=\"_blank\" rel=\"noopener\">info@aghealth.co.uk<\/a><br \/>Web: <a href=\"https:\/\/www.aghealth.co.uk\/wid-easy\" target=\"_blank\" rel=\"noopener\">www.aghealth.co.uk<\/a><\/p>\n<p>[\/et_pb_team_member][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_team_member name=&#8221;European Oncology Lab GmbH&#8221; position=&#8221;Klaus-Tussing-Str. 2 \/ Gesundheitspark 2, 66386 St. Ingbert, Germany &#8221; image_url=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/10\/EOL_Logo.png&#8221; admin_label=&#8221;European Oncology Lab&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; link_option_url=&#8221;https:\/\/www.europeanoncologylab.com&#8221; link_option_url_new_window=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Tel: +49 <span>6894 95310<\/span><br \/>Mail: <a href=\"mailto:labor@europeanoncologylab.com\" target=\"_blank\" rel=\"noopener\">labor@europeanoncologylab.com<\/a><br \/>Web: <a href=\"https:\/\/www.europeanoncologylab.com\" target=\"_blank\" rel=\"noopener\">www.europeanoncologylab.com<\/a><\/p>\n<p>[\/et_pb_team_member][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_team_member name=&#8221;labor team w ag&#8221; position=&#8221;Blumeneggstrasse 55, 9403 Goldach, Switzerland&#8221; image_url=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2024\/09\/labor_team_300px.png&#8221; admin_label=&#8221;Labor Team W AG&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; link_option_url=&#8221;https:\/\/www.laborteam.ch&#8221; link_option_url_new_window=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Tel: +41 71 844 45 45<br \/>Mail: <a href=\"mailto:info@team-w.ch\" target=\"_blank\" rel=\"noopener\">info@team-w.ch<\/a><br \/>Web: <a href=\"https:\/\/www.laborteam.ch\" target=\"_blank\" rel=\"noopener\">www.laborteam.ch<\/a><\/p>\n<p>[\/et_pb_team_member][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_team_member name=&#8221;Laboratory &#8211; Doz. DDr. Stefan Mustafa  &#8221; position=&#8221;Ziehrerplatz 9, 1030 Vienna, Austria&#8221; image_url=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2024\/09\/Logo_Labor_Mustafa-1.png&#8221; admin_label=&#8221;Labor Mustafa&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; link_option_url=&#8221;https:\/\/www.labor-mustafa.at&#8221; link_option_url_new_window=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Tel: +43 1 713 91 88<br \/>Mail: <a href=\"mailto:office@labor-mustafa.at\" target=\"_blank\" rel=\"noopener\">office@labor-mustafa.at<\/a><br \/>Web: <a href=\"https:\/\/www.labor-mustafa.at\" target=\"_blank\" rel=\"noopener\">www.labor-mustafa.at<\/a><\/p>\n<p>[\/et_pb_team_member][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,1_4,1_4,1_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_team_member name=&#8221;Medilab GmbH&#8221; position=&#8221;Strubergasse 20, 5020 Salzburg, Austria&#8221; image_url=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/06\/Medilab-1.png&#8221; admin_label=&#8221;Medilab&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; link_option_url=&#8221;https:\/\/www.medilab.at&#8221; link_option_url_new_window=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Tel: +43 662 2205<br \/>Mail: <a href=\"mailto:office@medilab.at\" target=\"_blank\" rel=\"noopener\">office@medilab.at<\/a><br \/>Web: <a href=\"https:\/\/www.medilab.at\" target=\"_blank\" rel=\"noopener\">www.medilab.at<\/a><\/p>\n<p>[\/et_pb_team_member][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_team_member name=&#8221;NextGen Molecular Supplies&#8221; position=&#8221;Incubation Drive 8, 2021 Midrand, South Africa&#8221; image_url=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/06\/NextGenMolecularSupplies.png&#8221; admin_label=&#8221;NextGen Molecular Supplies&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; link_option_url=&#8221;https:\/\/ngms.co.za&#8221; link_option_url_new_window=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Tel: +27 87 148 9309<br \/>Mail: <a href=\"mailto:customer_care@ngms.co.za\u00a1\" target=\"_blank\" rel=\"noopener\">customer_care@ngms.co.za<\/a><br \/>Web: <a href=\"https:\/\/ngms.co.za\" target=\"_blank\" rel=\"noopener\">www.ngms.co.za<\/a><\/p>\n<p>[\/et_pb_team_member][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_team_member name=&#8221;UAB Genotipas&#8221; position=&#8221;Avie\u010di\u0173 g. 14, 08418, Vilnius, Lithuania&#8221; image_url=&#8221;https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/06\/Genotipas_neu2-1.png&#8221; admin_label=&#8221;Genotipas&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; link_option_url=&#8221;https:\/\/www.genotipas.lt\/en\/cancer-tests\/uterine-endometrial-cancer-test-wid-easy&#8221; link_option_url_new_window=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Tel: +370 686 55909<br \/>Mail: <a href=\"mailto:info@genotipas.lt\" target=\"_blank\" rel=\"noopener\">info@genotipas.lt<\/a><br \/>Web: <a href=\"https:\/\/www.genotipas.lt\/en\/cancer-tests\/uterine-endometrial-cancer-test-wid-easy\" target=\"_blank\" rel=\"noopener\">www.genotipas.lt<\/a><\/p>\n<p>[\/et_pb_team_member][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.22.1&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Overview | Principle | Indication | Sampling | Performance | Your benefit | Literature | Availability Epigenetic DNA methylation test for the detection of all carcinomas originating from the uterus, especially endometrial carcinoma, but also endocervical carcinoma. The test is indicated in peri- and postmenopausal women with abnormal uterine bleeding. Sample collection by cervicovaginal swab. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-256880","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/pages\/256880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/comments?post=256880"}],"version-history":[{"count":30,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/pages\/256880\/revisions"}],"predecessor-version":[{"id":263972,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/pages\/256880\/revisions\/263972"}],"wp:attachment":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/media?parent=256880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}